Tag: the war on (some) drugs

Senators Condemn Russia Over American Citizen’s ‘Ludicrous’ Incarceration For Medical Marijuana

A coalition of more than 20 U.S. senators has filed a resolution condemning the arrests of American citizens in Russia, including a Pennsylvania medical cannabis patient, Marc Fogel, who is serving a a 14-year sentence over simple possession of marijuana.

Sponsored by Senate Majority Whip Dick Durbin (D-IL), the measure was filed to mark the one-year anniversary of the arrest of Wall Street Journal reporter Evan Gershkovich over unfounded allegations of espionage.

“By introducing this resolution, we’re yet again bringing to light the cruelty of the Russian government,” Durbin, who also chairs the Senate Judiciary Committee, said in a press release on Tuesday. “As fellow Americans, we demand the release of all American citizens who face arbitrary arrests by the Russian government.”

The senator said in a floor speech on Thursday that Fogel’s arrest over possession of medical cannabis he was prescribed in a legal state resulted in a “ludicrous 14-year sentence in Russian labor camps.”

Sen. John Fetterman (D-PA), who is among the prime cosponsors, said Fogel was “detained for carrying a small amount of medical marijuana, which was prescribed by his doctor.”

Keep reading

Record Number Of Truck Drivers Refuse To Take Drug Tests As More States Legalize Marijuana

As more states legalize marijuana, a new federal report shows that the number of positive drug tests among commercial drivers fell last year compared to the year before, dropping from 57,597 in 2022 to 54,464 in 2023. At the same time, however, the number of drivers who refused to be screened at all also increased by 39 percent.

The record-high number of refusals comes as the transportation industry faces a nationwide shortage of drivers, which some trade groups have said has only been made worse by drug testing policies that risk flagging drivers even when they’re not impaired on the job.

The rise in refusals meant that even though there were fewer positive tests overall in 2023, the total number of recorded drug violations among truckers actually rose slightly—to 68,229 in 2023 compared to 67,775 a year earlier.

“The overall rise in drug violations in 2023, even though there are fewer positive tests, is attributed to a nearly 40% increase in reported drug test refusals—9,214 in 2022 versus 12,804 in 2023,” the Federal Motor Carrier Safety Administration (FMCSA), which produced the new report, told the trade publication Transport Topics.

“Drug test refusals include employer reported refusals like failing to show up for a random test, or leaving a test collection facility after a test has begun but before it’s complete,” added FMCSA, an arm of the U.S. Department of Transportation.

Keep reading

Missouri Warns Marijuana License Applicants Of ‘Predatory Practices’ Around Social Equity Status

Veterans John and Kara Grady received a Facebook message last week from a man who was “looking for a female veteran to be part of our dispensary license.”

Being a veteran is one of the seven categories that makes people eligible to win one of the state’s social-equity marijuana licenses, called “microbusiness licenses.” The other categories range from having a lower income or living in an area considered impoverished to having past arrests or incarcerations related to marijuana offenses.

When the Gradys—who run Slaphappy Beverage Co., which sells hemp-derived THC drinks—turned him down, the man began attacking them on their social media pages.

“I was like, ‘What kind of tactics are these?’” John Grady said in an interview with The Independent. “You have to ask yourself—if it’s that competitive on the microbusiness licenses, then really what’s going on?”

Just hours before Grady received that message, the Missouri Division of Cannabis Regulation issued a warning about “predatory practices” in social-equity marijuana licensing throughout the country.

And those tactics are likely escalating, with the next round of applications running April 15 to 29.

“[The Division of Cannabis Regulation] has become aware of solicitation efforts by companies to apply for microbusiness licenses on behalf of qualified individuals with promises of future ownership in the license,” the agency said in a press release last week.

The division warned that some groups are scamming eligible people by giving them, “no agreements in place that would actually result in the eligible individuals being the owners of the license.”

The division recently revoked nine of the 48 social-equity cannabis licenses issued in October—following an investigation by The Independent that found some applicants thought they were partnering with the Michigan investor but in reality signed agreements requiring them to relinquish all control and profits of the business.

The revocations came just as the division was gearing up for the second round of microbusiness applications, and now the state is urging applicants to be extra careful regarding whom they partner with.

“Eligible individuals should exercise caution in accepting such arrangements as some of the solicitations may be predatory in nature,” the division’s Thursday press release states.

Because only 39 of the 48 microbusiness licenses were ultimately issued from the first round, the division will award one additional wholesale license and eight additional dispensary licenses in the upcoming round.

The owners of the revoked licenses have vowed to appeal, though nothing has been filed as of yet.

Keep reading

CIA Wants Congress to Expand Top-Secret Eavesdropping Program To ‘Fight Against Fentanyl Crisis’

The Central Intelligence Agency (CIA), along with other members of the U.S. intelligence community, are pushing for Congress to expand Section 702 of the Foreign Intelligence Surveillance Act of 1978 in order to fight the ongoing fentanyl crisis.

According to the Brennan Center of Justice, Section 702, “Authorizes the government to collect the communications of non-Americans located abroad without a warrant from a court. While this surveillance is supposed to target foreigners, it inevitably sweeps in Americans’ private phone calls, emails, and text messages too.”

USA Today has reported that top CIA officials spent most of 2023-2024 urging members of Congress to reauthorize Section 702 of the FISA Act of 1978.

However, CIA officials believe in its current form, Section 702 limits the intelligence community from targeting everyone involved in the fentanyl trade overseas and are advocating lawmakers to expand Section 702 so U.S. spies will have more liberty when it comes to going after criminals engaged in the fentanyl trade.

Many lawmakers are skeptical of expanding Section 702 due to the CIA previously misusing the law to spy on American citizens.

Keep reading

Federal Officials Are Suddenly Seizing Marijuana From State-Licensed Businesses, Leaving Industry Perplexed

Federal officials have been seizing hundreds of thousands of dollars worth of marijuana from state-licensed cannabis businesses in New Mexico in recent weeks—detaining industry workers in what appears to be a localized escalation of national prohibition enforcement even as the federal government has largely refrained from interfering with the implementation of state legalization laws in recent years.

New Mexico marijuana businesses report that the more than dozen U.S. Customs and Border Protection (CBP) seizures, particularly at interior checkpoints around the Las Cruces area, are a relatively new phenomenon. Since adult-use marijuana sales launched in the state in 2022, the operators say they’ve generally been able to transport their products to testing facilities and retailers without incident.

Starting around two months ago, however, the agency has evidently taken a more proactive approach to enforcing federal prohibition, taking hundreds of pounds of cannabis at the checkpoints inside the state. CBP is able to carry out its activities within 100 miles of the U.S. border.

“There’s a lot of really successful important cannabis producers and cannabis manufacturers operating south of those checkpoints,” Ben Lewinger, executive director of the New Mexico Cannabis Chamber of Commerce, told Marijuana Moment. “Basically, every road that you could take from the southern to the northern part of the state, you have to go through one of these checkpoints—and it’s just bifurcating the industry and making it impossible for people in the southern part of the state to get their products to anywhere in the central or northern part of the state.”

CBP has made at least 13 stops and seizures of state-legal marijuana products since February, Lewinger, said adding that he “wouldn’t be surprised if it’s twice that number.”

“I’m certain that it’s underreported,” he said. “I think there’s lots of people who still have that fear and the stigma, and they don’t want to rattle cages.”

Keep reading

Psychoactive drug made from HUMAN BONES that has seen addicts digging up GRAVES to get high leads to Sierra Leone declaring a national emergency – as ‘zombie’ narcotic sweeps through West Africa, killing a dozens a month

Sierra Leone has declared a national emergency over a psychoactive drug made from human bones.

The country has witnessed a sharp spike in abuse of the drug, kush, forcing police officers to guard cemeteries in the capital of Freetown, to stop young men from digging up skeletons to get high. 

Kush is a drug made from a variety of substances, including toxic chemicals, herbs, cannabis, disinfenctant but one of its main ingredients is ground-up human bone, as they contain traces of sulphur, which allegedly can enhance the drugs effect. 

In a nationwide broadcast yesterday, Sierra Leone’s President Bio said: ‘Our country is currently faced with an existential threat due to the ravaging impact of drugs and substance abuse, particularly the devastating synthetic drug kush.’

Although there is no official death toll linked to kush abuse, one doctor from Freetown, told the BBC ‘in recent months’ hundreds of young men had died from organ failure caused by the drug. 

Keep reading

NHS hippy crack heists: Hospitals are warned thieves are now stealing nitrous oxide ‘laughing’ gas to order – after law change made the canisters illegal

Nitrous oxide suppliers have warned the NHS to review their security after a spike in incidents of thefts since the gas was banned and reclassified as a class C drug.

BOC, the UK’s leading supplier of medicinal gasses, sent a letter to NHS staff revealing they have ‘received a number of reports of thefts related to medical nitrous oxide cylinders in recent weeks’.

The firm warned: ‘In light of the recent reclassification of nitrous oxide under the Misuse of Drugs Act, we feel it is important to draw your attention to the possibility that legitimate users of medical nitrous oxide may become a target of further thefts.’

In the letter, which MailOnline has seen, the supplier urged NHS hospitals and their customers to review their medical gas cylinder security to deter any potential misuse or theft.

It comes after a new law introduced in November classified nitrous oxide as a Class C drug and made it illegal to possess it for the purpose of getting high.

But youngsters were undeterred and vowed to carry on using it, with their demand now fueling cannister thefts from NHS hospitals across the country.

Keep reading

DARE Didn’t Make Kids ‘Say No’ to Drugs. It Normalized Police in Schools.

There’s no such thing as a universal millennial experience, but DARE comes close.

Starting in 1983, the Drug Abuse Resistance Education program sent police officers into classrooms to teach fifth- and sixth-graders about the dangers of drugs and the need, as Nancy Reagan famously put it, to “just say no.” DARE embraced an abstinence-only model in which any use of alcohol or drugs qualified as abuse and the only acceptable tactic was to abstain. Upon completing the 17-week program, students received a certificate and a T-shirt.

At its height, over 75 percent of American schools participated in the program, costing taxpayers as much as $750 million per year. Historian Max Felker-Kantor revisits DARE and its legacy in DARE to Say No: Policing and the War on Drugs in Schools, a new history of the program.

As a DARE graduate myself who wore the T-shirt long after it was fashionable (look, I liked the austere black-and-red color scheme), I vaguely recall presentations given by someone from the local police department. On one occasion, he told a student to act drunk and pretend to offer the class beer, while the rest of us screamed at her in reply. Another time, our officer-instructor went on a tangent about how “girls are just tougher these days,” before presumably tying it back to why it was imperative that we 10- and 11-year-olds resist any entreaties to shoot up heroin in our rural Georgia schoolyard. I recently learned to my horror that my wife won a poetry contest in her DARE program in Alaska—a poem that she then, mortified, had to read aloud during the DARE graduation ceremony.

In hindsight, DARE is primarily remembered as a joke, a bunch of cops acting out hokey anti-drug skits. By 1994, a decade after the program’s founding, studies clearly indicated that the DARE curriculum had little to no effect on rates of youth drug use. By the 2010s, it had become a popular source of irony and parody: When then–Attorney General Jeff Sessions praised the program’s effectiveness in 2017, DARE graduates noted on social media how they still smoke pot in their black-and-red shirts.

But while DARE didn’t “work” in the sense of keeping many kids from using drugs, Felker-Kantor argues the program was wildly successful at normalizing the presence of police, and the war on drugs, in people’s everyday lives.

Keep reading

The War on Drugs Is Also a War on Pain Patients

In a March 22 opinion column in the New York Times entitled “The DEA Needs to Stay Out of Medicine,” Vanderbilt University Medical Center associate professor of anesthesiology and pain management Shravani Durbhakula, MD, documents powerfully how patients suffering from severe pain—many of them terminal cancer patients—have become collateral casualties in the government’s war on drugs.

Decrying the Drug Enforcement Administration’s progressive tightening of opioid manufacturing quotas, Dr. Durbhakula writes:

In theory, fewer opioids sold means fewer inappropriate scripts filled, which should curb the diversion of prescription opioids for illicit purposes and decrease overdose deaths — right?

I can tell you from the front lines that that’s not quite right. Prescription opioids once drove the opioid crisis. But in recent years opioid prescriptions have significantly fallen, while overdose deaths have been at a record high. America’s new wave of fatalities is largely a result of the illicit market, specifically illicit fentanyl. And as production cuts contribute to the reduction of the already strained supply of legal, regulated prescription opioids, drug shortages stand to affect the more than 50 million people suffering from chronic pain in more ways than at the pharmacy counter.

Dr. Durbhakula provides stories of patients having to travel long distances to see their doctors in person due to DEA requirements about opioid prescriptions. However, despite their efforts, they find that many of the pharmacies do not have the opioids they require because of quotas. She writes:

Health care professionals and pharmacies in this country are chained by the Drug Enforcement Administration. Our patients’ stress is the result not of an orchestrated set of practice guidelines or a comprehensive clinical policy but rather of one government agency’s crude, broad‐​stroke technique to mitigate a public health crisis through manufacturing limits — the gradual and repeated rationing of how much opioids can be produced by legitimate entities.

In the essay, Dr.Durbhakula does not question or challenge the false narrative that the overdose crisis originated with doctors “overprescribing” opioids to their pain patients.

Keep reading

DEA Agrees To Hold Hearing On Proposed Ban Of Two Psychedelics Amid Pushback From Researchers

The Drug Enforcement Administration (DEA) has scheduled an administrative hearing to get additional feedback from experts about its renewed push to ban two psychedelics after abandoning its original scheduling proposal in 2022.

More than a year after DEA announced its intent to classify 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA), the agency has agreed to hold a hearing before issuing a final rule.

DEA Administrator Anne Milgram signed off on the hearing notice on Thursday. It says that the agency’s administrative law judge will convene the meeting on June 10, at the request of three interested parties, including Panacea Plant Sciences, which had filed a motion contesting the proposed scheduling action last year.

Panacea Plant Sciences founder and CEO David Heldreth told Marijuana Moment on Monday that the company is “prepared to fight the DEA attempt to schedule DOI & DOC.”

“Beyond the scheduling attempt, we believe the DEA administrative law judges and system are unconstitutional,” he said, arguing that there’s legal precedent based on prior Supreme Court rulings. “We expect to file federal challenges to the ALJ prior to the hearing.”

In its notice about the psychedelics ban last year, DEA said its arguments about the merits of the scheduling action remained the same as in its prior abandoned ban attempt. It is maintaining that DOI and DOC hold high abuse potential with no established medical value. But it also notably described a change in the process to request an administrative hearing, which left some with the impression that the agency was deliberately complicating the procedure in the face of likely challenges from the psychedelics research community.

But, ultimately, DEA accepted the multiple requests for a hearing.

“Upon review of the requests for hearings, I have authorized a hearing, and direct the Chief Administrative Law Judge to assign the matter to an Administrative Law Judge who will complete all prehearing procedures, conduct a due process hearing…and issue a recommended decision for the Agency’s review and action,” Milgram said.

A DEA spokesperson told Marijuana Moment on Monday that they expect the notice to be posted on the online docket on Tuesday.

DEA backed down off its original proposed ban of the psychedelics following challenges from Panacea and researchers from Emory University. It remains to be seen how the agency will navigate the scheduling issue following the hearing with experts.

DEA separately withdrew from a proposal to ban five different tryptamine psychedelics in 2022 amid sizable pushback from the research and advocacy communities.

Keep reading